Merck, nearing completion of $1B Gardasil manufacturing push, eyes 2023 to double production⁠—again

After running into HPV vaccine supply shortfalls throughout 2018 and 2019, Merck & Co. is now reaping the rewards of a more than $1 billion manufacturing investment.

The Gardasil maker has expanded human papillomavirus (HPV) vaccine capacity at its facility in Elkton, Virginia, to the tune of 120,000 square feet and 150 new jobs, Merck said Monday.